¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2024³â ´ëÇÑÀ̽ÄÇÐȸ Á¦20Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-03-30

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2024³â ´ëÇÑÀ̽ÄÇÐȸ Á¦20Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-03-30
±³À°ÀÏÀÚ : 2024-03-30
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2024³â ´ëÇÑÀ̽ÄÇÐȸ Á¦20Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇÑÀ̽ÄÇÐȸ
´ã´çÀÚ : ÀåÇÏÁ¤
¿¬¶ôó : 02-6207-8182  

À̸ÞÀÏ : kst@kstmeeting.org

±³À°Á¾·ù : ³»°ú, ¿Ü°ú

Âü¼®¿¹»óÀÎ : 500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 18 ½Ã°£ 20ºÐ

¼¼ºÎ¼ö°­·á : 160,000¿ø  

ºñ°í [»çÀüµî·Ï]Á¤È¸¿ø 100,000¿ø / ÁØȸ¿ø 50,000¿øºñȸ¿ø-Àü¹®ÀÇ 150,000¿ø / Àü°øÀÇ, ÄÚµð³×ÀÌÅÍ, °£È£»ç µî 70,000¿ø[ÇöÀåµî·Ï]Á¤È¸¿ø 120,000¿ø / ÁØȸ¿ø 60,000¿øºñȸ¿ø-Àü¹®ÀÇ 160,000¿ø / Àü°øÀÇ, ÄÚµð³×ÀÌÅÍ, °£È£»ç µî 80,000¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±âŸ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 08:00~08:22 (»ç)»ý¸íÀÕ±â 2023³â »ç¾÷º¸°í À̻■(»ý¸íÀÕ±â)

±âŸ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 08:22~08:44 KODA ±â°üº¸°í ¹®Àμº(Çѱ¹Àå±âÁ¶Á÷±âÁõ¿ø)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 08:44~09:06 Àå±âÀ̽ÄÄÚȣƮ ±¸Ãà ¹× ¿î¿µ; 10³â °£ÀÇ ¼º°ú ±è¸í¼ö(KOTRY, ¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 09:06~09:29 Àå±â ÀÎüÁ¶Á÷ ±âÁõ È°¼ºÈ­¸¦ À§ÇÑ ±âº» °èȹ ±èÁ¤¼÷(º¸°Çº¹ÁöºÎ)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 09:00~09:15 ÈÄ Å¸Å©·Î¸®¹«½º ´ë»ç Á¶Àý Àå³» ¸¶ÀÌÅ©·Îºñ¿È ±â¹Ý Ÿ°Ù Ž»ö ±èÁöÀº(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 08:15~08:30 Çѱ¹ °£ÀÌ½Ä ´ë±âÀÚ¿¡¼­ MELDNa ¹× MELD 3.0 ÀÇ »ç¸Á ¿¹Ãø·Â È®ÀÎ(validation) ¹× ³ú»çÀÚ °£ ºÐ¹è ¿øÄ¢¿¡ÀÇ Àû¿ë°¡´É¼º °ËÅä ±è´ö±â(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 08:30~08:45 Àå±âÀÌ½Ä ÄÚµð³×ÀÌÅÍÀÇ ÀηÂÇöȲ°ú Á÷¹«ºÐ¼® ÁÖ¸¸±â(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 08:45~09:00 ¹Ì´Ï¼­Å¬ DNA ±â¹Ý »ý¹°ÇÐÀûÁ¦Á¦ÀÇ Ã¼³» ¾à¹°»ý»ê±â¼úÀ» È°¿ëÇÑ Å»°¨ÀÛ À̽Ĺý °³¹ß ¹ÎÁö¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 08:00~08:15 B¼¼Æ÷ ±³Â÷¹ÝÀÀ°Ë»çÀÇ À¯¿ë¼º ¹× Àǹ«½ÃÇà Çʿ伺 Æò°¡¿¬±¸ ¹Ú±Ýº¸·¡(KODA)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 09:15~09:30 ºô¸®·çºó ³ª³ëÆÄƼŬÀÇ ½ÉÀå ÇãÇ÷-Àç°ü·ù ¼Õ»ó º¸È£ È¿°ú ÀÌÁÖÇÑ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 09:30~09:45 ±âÁõÀÚ ¹× À¯°¡Á· ¿¹¿ì»ç¾÷ Çã¼öÁø(KODA °¡Á·Áö¿øºÎ)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 09:45~10:15 ³ú»ç±âÁõÀÚ À¯°¡Á·ÀÇ Á¤´çÇÑ ¸ò: ÀÎÅÍºä ¿¬±¸¿¡ ±âÃÊÇÑ Á¦¾È ±èÁ¤¾Æ(µ¿¾ÆÀÇ´ë ÀÇ·áÀι®Çаú)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 10:10~10:30 Discussion ()

ÈÞ½Ä 03¿ù 30ÀÏ 4Ãþ·Îºñ 10:30~10:50 Coffee Break ()

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 10:50~11:05 Heart-Lung co-transplantation - perspective from heart ÇöÁØÈ£(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 11:05~11:20 Heart-Lung co-transplantation - perspective from lung ¹Ú»ùÀ̳ª(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 11:20~11:35 Revision process of lung allocation system Á¶¿ìÇö(ºÎ»êÀÇ´ë È£Èí±â³»°ú)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 11:35~11:50 Blood type O allocation policy issue  ±è°æÈñ(¼¼Á¾º´¿ø)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 11:50~12:20 Discussion ()

±âŸ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 12:20~12:40 General Assembly ()

½Ä»ç 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 12:40~13:40 Luncheon Symposium ()

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 13:40~14:00 What is new in post-transplant IgA nephropathy °­ÀºÁ¤(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 14:00~14:20 Post-transplant FSGS - prevention & management ±ÇÇö¿í(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 14:20~14:40 Management of recurrent complement-mediated glomerulopathy Á¶ÀåÈñ(°æºÏÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 14:40~15:00 Recurrence of connective tissue disease related nephropathy ÀÌÇѺñ(°¡Å縯ÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 15:00~15:10 Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 13:40~14:00 Predicting hepatosteatosis of living donor ÀÌÀç½Â(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 14:00~14:20 Feasibility and risk factors for LDLT with elderly donor À̳²ÁØ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 14:20~14:40 Reducing the limit of graft and remnant liver volume; how far could we go? ±èż®(°è¸íÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 14:40~15:00 Anatomical factors of graft influencing LDLT outcome ¹Ú±æÃá(¿ï»êÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 15:00~15:10 Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 13:40~13:58 Donor harvest process ¼Õ¼®È£(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 13:58~14:16 Perioperative infection prophylaxis ÀÌ»ó¿À(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 14:16~14:34 Inotropic/Chronotrophic support in early post-transplantation ±èÀÎö(°è¸íÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 14:34~14:52 Cardiac allograft vasculopathy in pediatric recipient: Impact of donor inherent atherosclerosis À¯Á¤Áø(¿¬¼¼ÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 2Ãþ 212-213È£ 14:52~15:10 Panel Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 211È£ 13:40~14:10 DCD ÁøÇà½Ã ±âÁõÀÚ ÁÖÄ¡ÀÇÀÇ °æÇè ±æÀº¹Ì(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 211È£ 14:10~14:40 DCD ÁøÇà½Ã ¼öÇýÀÚ ÁÖÄ¡ÀÇÀÇ °æÇè ÀÌÀç±Ù(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 211È£ 14:40~15:10 DCDÁøÇà½Ã Donor ÄÚµð³×ÀÌÅÍÀÇ °æÇè Â÷¼Ò¶ó(»ï¼º¼­¿ïº´¿ø)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 13:40~14:00 Banff 2022 kidney update ÃÖ¼ºÀº(Â÷ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 14:00~14:20 Artificial intelligence in transplant pathology ÀÌ°æºÐ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 14:20~14:40 Guidelines on the Detection of Alloantibodies in Solid Organ Transplantation ¼ÛÀº¿µ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 14:40~15:00 Korean guidelines on the prevention of CMV infection ±èÁ¤¿Á(Ãæ³²ÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 2Ãþ 214È£ 15:00~15:10 Discussion ()

ÈÞ½Ä 03¿ù 30ÀÏ 4Ãþ·Îºñ 15:10~15:30 Coffee Break ()

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 15:30~15:50 Can old be too old for kidney transplantation? ±è¸í±Ô(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 15:50~16:10 Significance of fraility and sarcopenia in transplantation ÀÌÁÖÇÑ(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 16:10~16:30 Immunosuppression strategy for elderly kidney transplant recipients ½Åº´Ã¶(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 16:30~16:50 Simultaneous pancreas/kidney transplantation in elderly patients ÃÖº´Çö(ºÎ»êÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ2-3 16:50~17:00 Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 15:30~15:50 Preoperative risk and early detection for bleeding after LT ÇÑ¿µ¼®(´ë±¸°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 15:50~16:10 Bleeding control by surgery: when and how ÀÌÀç±Ù(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 16:10~16:30 Bleeding control by embolization: when and how ÃÖÁø¿ì(¼­¿ïÀÇ´ë ¿µ»óÀÇÇаú)

±³À°½Ã°£ 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 16:30~16:50 Bleeding after donor hepatectomy ·ùÁ¦È£(ºÎ»êÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 4Ãþ ÄÁº¥¼ÇȦ 1 16:50~17:00 Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 15:30~15:48 ECMO-bridged transplantation ±è´Ù·¡(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 15:48~16:06 Immunologic sensitization following LVAD implantation È«Á¤¾Ö(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 16:06~16:24 BTT LVAD for HF with significant pulmonary hypertension ±è¾Æ¶÷(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 212-213È£ 16:24~16:42 Renal function in patients with BTT LVAD ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)

Åä·Ð 03¿ù 30ÀÏ 2Ãþ 212-213È£ 16:42~17:00 Panel Discussion ()

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 15:30~15:48 Time to bridge and time to delist Àü°æ¸¸(¼º±Õ°üÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 15:48~16:06 Role of single lung transplantation in Korea: single vs. Bilateral ±èÇÏÀº(¿¬¼¼ÀÇ´ë)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 16:06~16:24 Are we ready for DCD in lung transplantation? ÇÔ¼®Áø(¾ÆÁÖÀÇ´ë ÈäºÎ¿Ü°ú)

±³À°½Ã°£ 03¿ù 30ÀÏ 2Ãþ 214È£ 16:24~16:42 Marginal donor lung utilization: is it acceptable? ¹ÚÁö¸í(¼­¿ïÀÇ´ë È£Èí±â³»°ú)

Åä·Ð 03¿ù 30ÀÏ 2Ãþ 214È£ 16:42~17:00 Panel Discussion ¿ì¾Æ¶ó(¿¬¼¼ÀÇ´ë È£Èí±â³»°ú)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2024³â ´ëÇÑÀ̽ÄÇÐȸ Á¦20Â÷ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-03-30""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»óºÎÀ§Àå°ü Ç︮ÄÚ¹ÚÅÍÇÐȸ È£³²Áöȸ HELP ½ÉÆ÷Áö¿ò : 2024-03-30
´ÙÀ½±Û 2024³â ¼øõ¸¸ ¼ÒÈ­±â³»½Ã°æ ¼¼¹Ì³ª : 2024-03-30
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20467 ¼­¿ï 2024 ´ëÇÑÇ÷¾×ÇÐȸ Á¶Á÷±¸Áõ½ÄÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-31 0 76 2024-04-17
20466 °æ±â ¾ÆÁִ뺴¿ø ÀÀ±ÞÀÇÇаú ¼³¸³ 30Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2024-05-30 0 39 2024-04-17
20465 ¼­¿ï Á¦20Â÷ ´ëÇѸð¹ßÇÐȸ Çмú´ëȸ ÇÁ·Î±×·¥ : 2024-05-26 0 45 2024-04-17
20464 °æ±â 2024³â Á¦86Â÷ ´ëÇÑ»ý½ÄÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-26 0 34 2024-04-17
20463 ¼­¿ï 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Ãá°è ½ÉÆ÷Áö¾ö : 2024-05-26 0 25 2024-04-17
20462 ¼­¿ï ´ëÇÑÃæ°ÝÆÄÄ¡·áÇÐȸ 2024 Ãá°è Çмú´ëȸ : 2024-05-26 0 21 2024-04-17
20461 ¼­¿ï Áø´Ü ü°èÀû¹®Çå°íÂû ¿öÅ©¼¥ : 2024-05-25 0 30 2024-04-17
20460 ¼­¿ï ´ëÇѺñ¸¸ÇÐȸ Á¦17ȸ ODOT (One Day Course of Obesity Treatment) : 2024-05-25 0 24 2024-04-17
20459 ¼­¿ï 2024³â Á¾¾ç¸é¿ª´ÙÇÐÁ¦¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2024-05-24 0 16 2024-04-17
20458 ¼­¿ï 2024 Á¦12ȸ ´ëÇÑÇ÷¾×ÇÐȸ Ç÷¿ìº´¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2024-05-24 0 28 2024-04-17
20457 ¼­¿ï 2024³â ¿µµîÆ÷±¸ÀÇ»çȸ Ãá°è Çмú´ëȸ : 2024-05-21 0 31 2024-04-17
20456 ¼­¿ï 2024³â ´ëÇÑÀÓ»ó°Ç°­ÁõÁøÇÐȸ Ãá°èÇмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-19 0 32 2024-04-17
20455 ¼­¿ï Á¦7Â÷ ´ëÇѼö¸éÈ£ÈíÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-19 0 38 2024-04-17
20454 ¼­¿ï 2024 ´ëÇѼҾÆÇ÷¾×Á¾¾çÇÐȸ Ãá°è¿¬¼ö°­Á : 2024-05-18 0 26 2024-04-17
20453 ¼­¿ï 2024³â ´ëÇÑ¿¬ÇÏÀå¾ÖÇÐȸ Á¦14ȸ Ãá°èÇмú´ëȸ : 2024-05-18 0 31 2024-04-17
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷